- Email: [email protected]
Faculty Disclosures
Optimizing Insulin Therapy for Type 2 Diabetes
Guest Editor Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California
Faculty Stephen Brunton, MD Charlotte, North Carolina Arturo Rolla, MD Beth Israel Deaconess Medical Center Harvard Medical School Boston, Massachusetts
Joseph Tibaldi, MD Department of Endocrinology Flushing Hospital Medical Center Flushing, New York
Faculty Disclosures The authors who contributed to this publication have disclosed the following industry relationships:
Stephen Brunton, MD, serves on the advisory boards for Abbott Laboratories, Amylin Pharmaceuticals, Inc., AstraZeneca, and Novo Nordisk A/S. Arturo Rolla, MD, is a member of the Speakers’ Bureau for Eli Lilly and Company, GlaxoSmithKline, Novo Nordisk A/S, Takeda Pharmaceuticals North America, Inc., and Roche Laboratories. Joseph Tibaldi, MD, is a member of the Speakers’ Bureau for Daichi Sankyo, GlaxoSmithKline, Merck & Co., Novartis, Novo Nordisk A/S, and sanofi-aventis.
Jeff Unger, MD, is a member of the Speakers’ Bureau/ Advisory Boards for Eli Lilly, Pfizer Inc, AstraZeneca, GlaxoSmithKline, sanofi-aventis, Merck & Co., Kos, Ortho-McNeil, Inc., Novo Nordisk A/S, Novartis, Amylin Pharmaceuticals, Inc., Medtronic MiniMed, ProEthic, Primary Care Network (of which he is also a Board Member); has received received research grants from Eli Lilly and Company, Ortho-McNeil, Inc., Novo Nordisk, Amylin Pharmaceuticals, Inc.; is a stockholder with Pfizer Inc, sanofi-aventis, Amylin Pharmaceuticals, Inc.; and receives a salary from Quadrant Medical Education.
Guest Editor Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California
Faculty Stephen Brunton, MD Charlotte, North Carolina Arturo Rolla, MD Beth Israel Deaconess Medical Center Harvard Medical School Boston, Massachusetts
Joseph Tibaldi, MD Department of Endocrinology Flushing Hospital Medical Center Flushing, New York
Faculty Disclosures The authors who contributed to this publication have disclosed the following industry relationships:
Stephen Brunton, MD, serves on the advisory boards for Abbott Laboratories, Amylin Pharmaceuticals, Inc., AstraZeneca, and Novo Nordisk A/S. Arturo Rolla, MD, is a member of the Speakers’ Bureau for Eli Lilly and Company, GlaxoSmithKline, Novo Nordisk A/S, Takeda Pharmaceuticals North America, Inc., and Roche Laboratories. Joseph Tibaldi, MD, is a member of the Speakers’ Bureau for Daichi Sankyo, GlaxoSmithKline, Merck & Co., Novartis, Novo Nordisk A/S, and sanofi-aventis.
Jeff Unger, MD, is a member of the Speakers’ Bureau/ Advisory Boards for Eli Lilly, Pfizer Inc, AstraZeneca, GlaxoSmithKline, sanofi-aventis, Merck & Co., Kos, Ortho-McNeil, Inc., Novo Nordisk A/S, Novartis, Amylin Pharmaceuticals, Inc., Medtronic MiniMed, ProEthic, Primary Care Network (of which he is also a Board Member); has received received research grants from Eli Lilly and Company, Ortho-McNeil, Inc., Novo Nordisk, Amylin Pharmaceuticals, Inc.; is a stockholder with Pfizer Inc, sanofi-aventis, Amylin Pharmaceuticals, Inc.; and receives a salary from Quadrant Medical Education.